Division of Surgical Oncology, Erasmus University MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
J Surg Oncol. 2010 Oct 1;102(5):413-8. doi: 10.1002/jso.21618.
The traditional treatment for stage IV colorectal cancer has changed from palliative chemotherapy toward an aggressive multimodality approach. In the current study outcome in patients who underwent surgery for synchronous colorectal liver metastases (CLM) in a single center was evaluated.
From January 1991 to May 2008 all consecutive patients with synchronous CLM who underwent curative resection of both primary and metastatic disease were included. Date of resection was divided into two groups: date of hepatic resection before and after the year 2000.
Fifty patients (26%) with synchronous CLM were resected before 2000 and 142 patients (74%) underwent resection after 2000. The estimated 5-year disease-free survival before and after 2000 was 9% and 27%, respectively (P = 0.379). More patients who underwent resection after 2000 were treated with local therapy or underwent resection for intra-hepatic recurrence (62% vs. 28%, P = 0.033). The estimated 5-year survival before and after 2000 was 26% and 44%, respectively (P = 0.001).
Survival rates in patients with synchronous CLM have been increased in the past decade. The introduction of new chemotherapeutic drugs and a more aggressive treatment approach in patients with liver recurrence were probably major factors in this progress.
传统的 IV 期结直肠癌治疗已从姑息性化疗转变为积极的多模式治疗。本研究评估了单一中心接受同步结直肠肝转移(CLM)手术治疗的患者的结局。
1991 年 1 月至 2008 年 5 月,所有接受同步 CLM 根治性切除的患者均包括在内。手术日期分为两组:2000 年之前和之后的肝切除术日期。
50 例(26%)同步 CLM 患者于 2000 年前接受手术,142 例(74%)于 2000 年后接受手术。2000 年前和 2000 年后的 5 年无病生存率分别为 9%和 27%(P=0.379)。更多的 2000 年后接受手术的患者接受了局部治疗或接受了肝内复发的切除术(62%比 28%,P=0.033)。2000 年前和 2000 年后的 5 年生存率分别为 26%和 44%(P=0.001)。
过去十年中,同步 CLM 患者的生存率有所提高。引入新的化疗药物和对肝复发患者采取更积极的治疗方法可能是取得这一进展的主要因素。